BioCentury
ARTICLE | Top Story

Zafgen jumps on beloranib Prader-Willi data

January 21, 2016 1:51 AM UTC

Zafgen Inc. (NASDAQ:ZFGN) jumped $4.42 (79%) to $10.04 on Wednesday after it said subcutaneous beloranib ( ZGN-440) met the co-primary endpoints of significantly reducing both body weight and hyperphagia-related behaviors vs. placebo in the randomized portion of the Phase III bestPWS (ZAF-311) trial to treat Prader-Willi syndrome.

Zafgen shares remain well below their Oct. 9 close of $34.40, before Zafgen revealed the first of two deaths of patients receiving beloranib in the trial. Both patients experienced pulmonary emboli. Last month, FDA placed a full clinical hold on studies of the methionine aminopeptidase 2 ( MetAP2) inhibitor (see BioCentury, Dec. 14, 2015). ...